Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04294368 · ClinicalTrials.gov registry record · NA
Targeted Fortification of Donor Breast Milk in Preterm Infants
A NA study of Prematurity; Extreme and Growth Failure, sponsored by Columbia University.
- Recruiting
- Registry status
- NA
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT04294368 is a NA study of Prematurity; Extreme and Growth Failure that is actively recruiting participants, run by Columbia University. The registered enrollment target is 50 participants, below the 235-participant average among 4 other Prematurity; Extreme trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04294368, a NA study of Prematurity; Extreme and Growth Failure, is actively recruiting participants, sponsored by Columbia University.
- RECRUITING
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is a randomized controlled trial comparing standard fortification of donor breast milk to targeted fortification of donor breast milk in preterm infants. The purpose of the study is to determine if there is a benefit to target fortifying donor breast milk in the preterm population. The investigators hypothesize that infants receiving targeted fortification of donor breast milk will have improved growth compared to infants receiving standard fortification of donor breast milk.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Similac Human Milk Fortifier Extensively Hydrolyzed Protein Concentrated Liquid
- DIETARY_SUPPLEMENT Similac Liquid Protein Fortifier
- DIETARY_SUPPLEMENT Nestle Microlipid
- DIETARY_SUPPLEMENT Medica Nutrition SolCarb
- DIETARY_SUPPLEMENT Similac Human Milk Fortifier Extensively Hydrolyzed Protein Concentrated Liquid (Targeted Fortification)
Study Locations (1)
New York
- Columbia University Medical Center/ New York - Presbyterian - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2020-03-09 |
| Est. Completion | 2026-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04294368
The ClinicalTrials.gov registry entry for NCT04294368 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 235-participant average among 4 other Prematurity; Extreme trials with a reported enrollment target (79% lower). The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Prematurity; Extreme appearing as the primary indexed condition, and to 5 interventions - of which Similac Human Milk Fortifier Extensively Hydrolyzed Protein Concentrated Liquid is the first listed.
NCT04294368 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT04294368 about?
NCT04294368 is a clinical study titled "Targeted Fortification of Donor Breast Milk in Preterm Infants". This study is a randomized controlled trial comparing standard fortification of donor breast milk to targeted fortification of donor breast milk in preterm infants. The purpose of the study is to determine if there is a benefit to target fortifying donor breast milk in the preterm population. The in...
What is the current status of trial NCT04294368?
This trial is currently recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2020-03-09. Estimated completion is 2026-03.
What conditions does trial NCT04294368 study?
This clinical trial studies the following conditions: Prematurity; Extreme, Growth Failure, Growth Retardation, Failure to Thrive in Newborn, Infant Nutrition Disorders.
What interventions are being tested in trial NCT04294368?
The interventions under investigation include: Similac Human Milk Fortifier Extensively Hydrolyzed Protein Concentrated Liquid (DIETARY_SUPPLEMENT), Similac Liquid Protein Fortifier (DIETARY_SUPPLEMENT), Nestle Microlipid (DIETARY_SUPPLEMENT), Medica Nutrition SolCarb (DIETARY_SUPPLEMENT), Similac Human Milk Fortifier Extensively Hydrolyzed Protein Concentrated Liquid (Targeted Fortification) (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT04294368?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04294368 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prematurity; Extreme
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Early Protein Supplementation in Extremely Preterm Infants Fed Human Milk
ACTIVE NOT RECRUITING · NA
-
Use of NIRS in Preterm Population Born at Altitude
COMPLETED · NA
-
The Budesonide in Babies (BiB) Trial
ACTIVE NOT RECRUITING · Phase 3
-
Respiratory Outcomes After Early Vitamin D Supplementation in Infants Born Extremely Preterm
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.